Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Stuttgart - Delayed Quote EUR

Financière de Tubize SA (FTD.SG)

Compare
150.00
+2.80
+(1.90%)
As of 10:26:05 AM GMT+1. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Cost of Revenue
2,077.59
2,077.59
1,828.07
1,497.05
--
Gross Profit
-2,077.59
-2,077.59
-1,828.07
-1,497.05
--
Operating Expense
0.96
0.96
-5.29
36.52
2,249
Operating Income
-2,078.55
-2,078.55
-1,822.78
-1,533.57
-2,249
Net Non Operating Interest Income Expense
-3,343.30
-3,343.30
-2,039.17
85,080.19
-1,098
Pretax Income
88,151.27
88,151.27
85,169.89
83,602.31
260,519
Net Income Common Stockholders
88,151.27
88,151.27
85,169.89
83,602.31
260,519
Diluted NI Available to Com Stockholders
88,151.27
88,151.27
85,169.89
83,602.31
260,519
Basic EPS
1.98
1.98
1.91
1.88
5.85
Diluted EPS
1.98
1.98
1.91
1.88
5.85
Basic Average Shares
44,512.60
44,512.60
44,512.60
44,512.60
44,512.60
Diluted Average Shares
44,512.60
44,512.60
44,512.60
44,512.60
44,512.60
Total Expenses
2,078.55
2,078.55
1,822.78
1,533.57
2,249
Net Income from Continuing & Discontinued Operation
88,151.27
88,151.27
85,169.89
83,602.31
260,519
Normalized Income
-5,421.87
-5,421.87
-3,863.24
83,582.49
260,395
Interest Income
10.75
10.75
--
86,457.77
--
Interest Expense
3,294.65
3,294.65
1,718.79
1,315.38
543
Net Interest Income
-3,343.30
-3,343.30
-2,039.17
85,080.19
-1,098
EBIT
91,445.91
91,445.91
86,888.68
84,917.69
261,062
EBITDA
91,445.91
91,445.91
86,888.68
84,917.69
261,062
Reconciled Cost of Revenue
2,077.59
2,077.59
1,828.07
1,497.05
--
Net Income from Continuing Operation Net Minority Interest
88,151.27
88,151.27
85,169.89
83,602.31
260,519
Total Unusual Items Excluding Goodwill
93,573.14
93,573.14
89,033.13
19.82
124
Total Unusual Items
93,573.14
93,573.14
89,033.13
19.82
124
Normalized EBITDA
-2,127.23
-2,127.23
-2,144.45
84,897.87
260,938
12/31/2020 - 1/18/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

222110.KQ PanGen Biotech Inc.
5,240.00
+4.59%
 
ICY.F Incyte Corporation
66.78
-5.06%
 
22Z.F Zealand Pharma A/S
80.30
-0.93%
 
UCBJF UCB SA
201.97
+5.19%
 
SANN.SW Santhera Pharmaceuticals Holding AG
15.78
-1.74%
 
VCEL Vericel Corporation
49.51
-3.47%
 
ATYR aTyr Pharma, Inc.
3.3000
-16.56%
 
GERN Geron Corporation
1.7100
-2.84%